Cisplatin plus Epirubicin plus Cyclophosphamide

Phase 2Small molecule

Cisplatin plus Epirubicin plus Cyclophosphamide is one of 26 small molecule programs targeting Thymoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ThymomaActive, not recruiting

ThymomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

26 competitors in Thymoma

#DrugCompanyPhaseTrials

Vepesid

AAvyxa

Approved

—2

Betadine

BBecton, Dickinson and Company

Signifor

Beleodaq

AAcrotech Biopharma Inc.

Medrol

1 6

Sandostatin

Novartis

Phase 2

1 7

Taxol

Teva

Phase 2

1 8

Sutent

Rayos

1 10

Tarceva

DDutch Society of Physicians for Pulmonology and Tuberculosis

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Thymoma1 trial

The Efficacy and Safety of Nanoparticle Albumin-bound (NAB)-Paclitaxel Plus Cisolation Versus CEP (Cisplatin, Epirubicin,Cyclophosphamide) in Induction Therapy for Thymoma: a Study for a Single-center Prospective Phase II Randomized Controlled Train.

Not yet recruiting·PPeng Liu·Phase 2·NCT05816694·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Cisplatin plus Epirubicin plus Cyclophosphamide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cisplatin plus Epirubicin plus Cyclophosphamide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cisplatin plus Epirubicin plus Cyclophosphamide. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Peng Liu company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: PPeng Liu

Cisplatin plus Epirubicin plus Cyclophosphamide

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Thymoma1 trial

References

Drug Info

Quick Facts

Related News